P53 overexpression predicts unfavorable prognosis of low risk endometrial carcinoma

Aim: Mutations of PTEN, p53 are the most frequent molecular defects in endometrial carcinomas (EC). Aim of this study was to investigate their prognostic significance in EC, especially for low risk EC. Materials and Methods: This retrospective study included 99 patients with diagnosed endometrial adenocarcinoma. Paraffin embedded specimens were studied immunohistochemically for detection of PTEN, p53 proteins. Correlation of p53 overexpression and loss expression of PTEN with several well-established prognostic parameters and survival rate were evaluated. Result: Overexpression of p53 was an independent prognostic factor for EC. Stratified analysis showed that p53 overexpression was a significant prognostic factor for low-grade (p < 0. 0001), early -stage (p < 0.0001), EC (< 0.0001), and non-nodal metastasis ones, but not for high-grade (p = 0.080), type II EC (p = 0.056), advanced EC (p = 0.632) or nodal metastasis ones (p = 0. 660). The present study failed to demonstrate that loss expression of PTEN was correlated with survival rate of EC. Conclusion: p53 overexpression was an independent prognostic factor of EC, especially for low-grade, early-stage, EC and nonnodal metastasis ones. Loss expression of PTEN was not correlated with survival rate of EC.

p53; PTEN; Endometrial carcinoma; Immunohistochemistry; Prognosis.

[1] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al.: “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. Int. J. Cancer, 2015, 136, E359.

[2] Prat J., Gallardo A., Cuatrecasas M., Catasús L.: “Endometrial carcinoma: pathology and genetics”. Pathology, 2007, 39, 72.

[3] Lax S.F.: “Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification”. Virchows Arch., 2004, 444, 213.

[4] Kanamori Y., Kigawa J., Itamochi H., Sultana H., Suzuki M., Ohwada M., et al.: “PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy”. Int. J. Cancer, 2002, 100, 686.

[5] Athanassiadou P., Athanassiades P., Grapsa D., Gonidi M., Athanassiadou A.M., Stamati P.N., et al.: “The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study”. Int. J. Gynecol. Cancer, 2007, 17, 697.

[6] Kalogiannidis I., Bobos M., Papanikolaou A., Makedos A., Amplianitis I., Vergote I., et al.: “Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes”. Eur. J. Gynaecol. Oncol., 2008, 29, 19.

[7] Inaba F., Kawamata H., Teramoto T., Fukasawa I., Inaba N., Fujimori T.: “PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma”. Oncol. Rep., 2005, 13, 17.

[8] Minaguchi T., Yoshikawa H., Oda K., Ishino T., Yasugi T., Onda T., et al.: “PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas”. Clin. Cancer Res., 2001, 7, 2636.

[9] Ballester M., Dubernard G., Lécuru F., Heitz D., Mathevet P., Marret H., et al.: “Detection rate and diagnostic accuracy of sentinelnode biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO)”. Lancet Oncol., 2011, 12, 469.

[10] Sorbe B.G., Horvath G., Andersson H., Boman K., Lundgren C., Pettersson B.: “External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study--quality-of-life analysis”. Int. J. Gynecol. Cancer, 2012, 22, 1281.

[11] Bendifallah S., Canlorbe G., Raimond E., Hudry D., Coutant C., Graesslin O., et al.: “A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion”. Br. J. Cancer, 2014, 110, 2640.

[12] Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C., et al.: “Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2013, 24, vi33.

[13] Sorosky J.I.: “Endometrial cancer”. Obstet Gynecol., 2008, 111, 436.

[14] Jeon Y.T., Kang S., Kang D.H., Yoo K.Y., Park I.A., Bang Y.J., et al.: “Cyclooxygenase-2 and p53 expressions in endometrial cancer”. Cancer Epidemiol Biomarkers Prev., 2004, 13, 1538.

[15] Jeczen R., Skomra D., Cybulski M., Schneider-Stock R., Szewczuk W., Roessner A., et al.: “P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome”. Clin Exp Metastasis., 2007, 24, 503.

[16] Vogelstein B., Lane D., Levine A.J.: “Surfing the p53 network”. Nature., 2000, 408, 307.

[17] Zheng W., Cao P., Zheng M., Kramer E.E., Godwin T.A.: “p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes”. Gynecol. Oncol., 1996, 61, 167.

[18] Alkushi A., Lim P., Coldman A., Huntsman D., Miller D., Gilks C.B.: “Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level”. Int. J. Gynecol. Pathol., 2004, 23, 129.

[19] Erdem O., Erdem M., Dursun A., Akyol G., Erdem A.: “Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables”. Int. J. Gynecol. Pathol., 2003, 22, 254.

[20] Ito K., Watanabe K., Nasim S., Sasano H., Sato S., Yajima A., et al.: “Prognostic significance of p53 overexpression in endometrial cancer”. Cancer Res., 1994, 54, 4667.

[21] Macwhinnie N., Monaghan H.: “The use of P53, PTEN, and C-erbB2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma”. Int. J. Gynecol Cancer, 2004, 14, 938.

[22] Kapucuoglu N., Aktepe F., Kaya H., Bircan S., Karahan N., Ciriş M.: “Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index”. Pathol. Res. Pract., 2007, 203, 153.

[23] Norimatsu Y., Moriya T., Kobayashi T.K., Sakurai T., Shimizu K., Tsukayama C., et al.: “Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women”. Ann. Diagn. Pathol., 2007, 11, 103.

[24] Erkanli S., Kayaselcuk F., Kuscu E., Bagis T., Bolat F., Haberal A., et al.: “Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium”. Int. J. Gynecol. Cancer, 2006, 16, 1412.

[25] Uegaki K., Kanamori Y., Kigawa J., Kawaguchi W., Kaneko R., Naniwa J., et al.: “PTEN-positive and phosphorylated-Aktnegative expression is a predictor of survival for patients with advanced endometrial carcinoma”. Oncol. Rep., 2005, 14, 389.

[26] Risinger J.I., Hayes K., Maxwell G.L., Carney M.E., Dodge R.K., Barrett J.C., et al.: “PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics”. Clin. Cancer Res., 1998, 4, 3005.